ATE510853T1 - Tlr2-antagonistischer antikörper und dessen verwendung - Google Patents

Tlr2-antagonistischer antikörper und dessen verwendung

Info

Publication number
ATE510853T1
ATE510853T1 AT04765554T AT04765554T ATE510853T1 AT E510853 T1 ATE510853 T1 AT E510853T1 AT 04765554 T AT04765554 T AT 04765554T AT 04765554 T AT04765554 T AT 04765554T AT E510853 T1 ATE510853 T1 AT E510853T1
Authority
AT
Austria
Prior art keywords
directed
antibody
prevention
nucleic acid
treatment
Prior art date
Application number
AT04765554T
Other languages
English (en)
Inventor
Carsten Kirschning
Guangxun Meng
Hermann Wagner
Original Assignee
Univ Muenchen Tech
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech, Amgen Inc filed Critical Univ Muenchen Tech
Application granted granted Critical
Publication of ATE510853T1 publication Critical patent/ATE510853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04765554T 2003-09-23 2004-09-23 Tlr2-antagonistischer antikörper und dessen verwendung ATE510853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03021461 2003-09-23
PCT/EP2004/010700 WO2005028509A1 (en) 2003-09-23 2004-09-23 Tlr2 antagonistic antibody and use thereof

Publications (1)

Publication Number Publication Date
ATE510853T1 true ATE510853T1 (de) 2011-06-15

Family

ID=34354423

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765554T ATE510853T1 (de) 2003-09-23 2004-09-23 Tlr2-antagonistischer antikörper und dessen verwendung

Country Status (4)

Country Link
US (2) US8623353B1 (de)
EP (1) EP1664118B1 (de)
AT (1) ATE510853T1 (de)
WO (1) WO2005028509A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623353B1 (en) 2003-09-23 2014-01-07 Technische Universitat Munchen TLR2 antagonistic antibody and use thereof
DE602005021694D1 (de) 2004-12-10 2010-07-15 Novimmune Sa Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
US20100143336A1 (en) * 2007-04-26 2010-06-10 Opsona Therapeutics Limited Toll-like receptor binding epitope and compositions for binding thereto
SI2173381T1 (sl) 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
EP2170392A2 (de) 2007-06-28 2010-04-07 Opsona Therapeutics Limited Zusammensetzungen und verfahren zur behandlung von autoimmunkrankheiten
AU2008285626B2 (en) * 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
IE20090514A1 (en) * 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
EP2812434B1 (de) * 2012-02-09 2018-03-28 Bavarian Nordic A/S Agonisten und antagonisten des toll-like-rezeptors (tlr) 13
GB201205633D0 (en) 2012-03-30 2012-05-16 Opsona Therapeutics Ltd Toll-like receptor 2 binding epitope and binding members thereto
EP2722342A1 (de) 2012-10-19 2014-04-23 Opsona Therapeutics Limited Verfahren und Zusammensetzungen zur Behandlung von Pankreaskrebs
US10047164B2 (en) 2012-10-19 2018-08-14 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
EP2970496B1 (de) 2013-03-12 2018-07-18 Institute of Arthritis Research LLC Immunologisch aktives polypeptid
JP6579097B2 (ja) 2014-02-28 2019-09-25 アステラス製薬株式会社 新規ヒトｔｌｒ２及びヒトｔｌｒ４に結合する二重特異的抗体
US20170137820A1 (en) * 2014-08-06 2017-05-18 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
JP6953033B2 (ja) * 2015-07-13 2021-10-27 ユニヴェルシテ ラヴァル ヒト化抗ｓ１００ａ９抗体およびその使用
US10196453B2 (en) * 2016-05-20 2019-02-05 University Of Virginia Patent Foundation Compositions and methods for treating Clostridium difficile infection
WO2018099614A1 (en) 2016-12-02 2018-06-07 Opsona Therapeutics Limited Methods and compositions for the treatment of myelodysplastic syndrome
EP3583949A1 (de) 2018-06-19 2019-12-25 Opsona Therapeutics Limited Toll-like rezeptor 2 (tlr2) antagonisten zur behandlung von ovarialkrebs
EP3864048A1 (de) 2018-10-11 2021-08-18 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Bakterien, die einzelkettige antikörper gegen toll-ähnliche rezeptoren exprimieren
CN111393530A (zh) * 2020-03-30 2020-07-10 中国人民解放军南部战区总医院 新人源tlr2胞外区段单克隆抗体及其制备方法和应用
CN111440240A (zh) * 2020-03-30 2020-07-24 中国人民解放军南部战区总医院 一种单克隆抗体及其制备方法和应用
US20220257633A1 (en) * 2021-02-17 2022-08-18 The Provost, Fellows, Foundation Scholars, & The O Method of treating age-related macular degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
JP4790937B2 (ja) 2001-07-09 2011-10-12 ティーピーオー ホンコン ホールディング リミテッド 反射電極を形成する方法及び液晶表示装置
AU2003209623A1 (en) * 2002-02-19 2003-09-09 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
US8623353B1 (en) 2003-09-23 2014-01-07 Technische Universitat Munchen TLR2 antagonistic antibody and use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
DE602005021694D1 (de) * 2004-12-10 2010-07-15 Novimmune Sa Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung

Also Published As

Publication number Publication date
WO2005028509A1 (en) 2005-03-31
US20140343256A1 (en) 2014-11-20
US8623353B1 (en) 2014-01-07
EP1664118A1 (de) 2006-06-07
EP1664118B1 (de) 2011-05-25
US9458234B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
MX2007001338A (es) Anticuerpos antagonistas de il-17.
NZ594682A (en) Fully human antibodies specific to cadm1
CY1118949T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
IL200373A (en) A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans
MX2010003574A (es) Anticuerpos il-23.
NZ600022A (en) Anti CD37 antibodies
NZ603499A (en) Human cytomegalovirus neutralizing antibodies and uses thereof
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
TW200503721A (en) Aminoquinoline compounds
NZ596295A (en) Anti-5T4 antibodies and uses thereof
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PH12013500347A1 (en) Antibodies to matrix metalloproteinase 9
GEP20104922B (en) Antibodies to m-csf
EP3255063A3 (de) Antikörper gegen matrix-metalloproteinase-9
ATE382053T1 (de) System zur antikörperexpression und- synthese
NZ601271A (en) Cd127 binding proteins
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
GB201005064D0 (en) Biological products
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
MX2009006891A (es) Anticuerpos cd44.
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
Geoghegan et al. Staphylococcus pseudintermedius expresses surface proteins that closely resemble those from Staphylococcus aureus
WO2022020234A3 (en) Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor
PE20240589A1 (es) ANTICUERPOS CD1a Y SU USO

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties